Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
102 USD | -1.92% | -0.98% | -7.38% |
May. 23 | Medtronic beats quarterly profit estimates on medical devices strength | RE |
May. 22 | Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 30.39 and 25.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.47 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.56% | 181B | C+ | ||
-0.11% | 108B | C | ||
-6.17% | 66.12B | A | ||
+2.64% | 50.65B | B- | ||
+6.58% | 43.11B | B- | ||
+3.49% | 40.74B | B+ | ||
+21.98% | 31.6B | B | ||
+16.38% | 25.56B | A- | ||
-5.81% | 24.16B | A- | ||
-4.35% | 23.95B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABT Stock
- Ratings Abbott Laboratories